Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
Adherence to quality metrics in early-stage NSCLC improves outcomes, but disparities exist among certain demographics, highlighting the need for equitable healthcare practices. Cemiplimab plus ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results